ClearPoint Neuro holder reports 7.8% ownership stake
ClearPoint Neuro, Inc. has a Schedule 13G/A filed by MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman reporting their ownership of the company’s common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ClearPoint Neuro, Inc. has a Schedule 13G/A filed by MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman reporting their ownership of the company’s common stock. The reporting persons collectively beneficially own 2,375,861 shares of common stock, representing 7.8% of the outstanding class as of June 30, 2026, based on 30,504,227 shares outstanding as of July 27, 2026.
The reporting persons report 0 shares with sole voting or dispositive power and 2,375,861 shares with shared voting and shared dispositive power. The amendment is signed by Michael A. Kaufman in his capacity as managing member and individual reporting person.
Key Figures
Key Terms
beneficially owned financial
Schedule 13G/A regulatory
percent of class financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in CLPT does MAK Capital report in this Schedule 13G/A?
Who are the reporting persons in the ClearPoint Neuro (CLPT) Schedule 13G/A?
What type of ClearPoint Neuro (CLPT) securities are covered in this Schedule 13G/A?
AI-generated analysis. How Rhea-AI works. Not financial advice.